Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    18596824 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
Conditions: Metastatic Renal Cell Carcinoma;   Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed
Intervention: Drug: Association of Bevacizumab (BVC)+ Pazopanib (PZP)

Study has passed its completion date and status has not been verified in more than two years.